Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
64
EYPT Quote, Financials, Valuation and Earnings
Last price:
$18.27
Seasonality move
:
6.32%
Day range:
$18.05 - $18.77
52-week range:
$3.91 - $19.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
29.59x
P/B ratio:
7.55x
Volume:
431.6K
Avg. volume:
1.3M
1-year change:
149.11%
Market cap:
$1.5B
Revenue:
$43.3M
EPS (TTM):
-$2.99
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EYPT
EyePoint Plc
|
$3.3M | -$0.77 | -91.32% | -16.98% | $36.08 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$10.6M | -$1.90 | 12.2% | -14.88% | $35.25 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$130.5M | -$1.05 | -32.42% | -80.04% | $87.99 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.67 | -- | -182.02% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EYPT
EyePoint Plc
|
$18.26 | $36.08 | $1.5B | -- | $0.00 | 0% | 29.59x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$29.19 | $35.25 | $1.7B | 3.91x | $0.00 | 0% | 37.58x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$80.65 | $87.99 | $13.1B | -- | $0.00 | 0% | 13.73x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
VKTX
Viking Therapeutics, Inc.
|
$37.35 | $93.39 | $4.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EYPT
EyePoint Plc
|
10.41% | 2.852 | 2.35% | 6.81x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.35% | 3.272 | 1.9% | 12.81x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.444 | 19.43% | 2.51x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 1.448 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EYPT
EyePoint Plc
|
$245K | -$62M | -72.69% | -79.15% | -6420.81% | -$60.2M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$9.8M | -$116.9M | -26.57% | -27.53% | -907.37% | -$89.7M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
EyePoint Plc vs. Competitors
-
Which has Higher Returns EYPT or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of -6183.44% compared to EyePoint Plc's net margin of -803.05%. EyePoint Plc's return on equity of -79.15% beat Agios Pharmaceuticals, Inc.'s return on equity of -27.53%.
Company Gross Margin Earnings Per Share Invested Capital EYPTEyePoint Plc25.36% -$0.85 $223.4M AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B -
What do Analysts Say About EYPT or AGIO?
EyePoint Plc has a consensus price target of $36.08, signalling upside risk potential of 97.61%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $35.25 which suggests that it could grow by 30.64%. Given that EyePoint Plc has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe EyePoint Plc is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EYPTEyePoint Plc10 0 0 AGIOAgios Pharmaceuticals, Inc.7 3 0 -
Is EYPT or AGIO More Risky?
EyePoint Plc has a beta of 1.668, which suggesting that the stock is 66.808% more volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.867, suggesting its less volatile than the S&P 500 by 13.282%.
-
Which is a Better Dividend Stock EYPT or AGIO?
EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EYPT or AGIO?
EyePoint Plc quarterly revenues are $966K, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $12.9M. EyePoint Plc's net income of -$59.7M is higher than Agios Pharmaceuticals, Inc.'s net income of -$103.4M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 29.59x versus 37.58x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EYPTEyePoint Plc29.59x -- $966K -$59.7M AGIOAgios Pharmaceuticals, Inc.37.58x 3.91x $12.9M -$103.4M
-
Which has Higher Returns EYPT or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of -6183.44% compared to EyePoint Plc's net margin of -82.06%. EyePoint Plc's return on equity of -79.15% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital EYPTEyePoint Plc25.36% -$0.85 $223.4M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About EYPT or IONS?
EyePoint Plc has a consensus price target of $36.08, signalling upside risk potential of 97.61%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 9.1%. Given that EyePoint Plc has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe EyePoint Plc is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EYPTEyePoint Plc10 0 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is EYPT or IONS More Risky?
EyePoint Plc has a beta of 1.668, which suggesting that the stock is 66.808% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.
-
Which is a Better Dividend Stock EYPT or IONS?
EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EYPT or IONS?
EyePoint Plc quarterly revenues are $966K, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. EyePoint Plc's net income of -$59.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 29.59x versus 13.73x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EYPTEyePoint Plc29.59x -- $966K -$59.7M IONSIonis Pharmaceuticals, Inc.13.73x -- $156.7M -$128.6M
-
Which has Higher Returns EYPT or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -6183.44% compared to EyePoint Plc's net margin of -255.85%. EyePoint Plc's return on equity of -79.15% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital EYPTEyePoint Plc25.36% -$0.85 $223.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About EYPT or NBY?
EyePoint Plc has a consensus price target of $36.08, signalling upside risk potential of 97.61%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that EyePoint Plc has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe EyePoint Plc is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EYPTEyePoint Plc10 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is EYPT or NBY More Risky?
EyePoint Plc has a beta of 1.668, which suggesting that the stock is 66.808% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock EYPT or NBY?
EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. EyePoint Plc pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EYPT or NBY?
EyePoint Plc quarterly revenues are $966K, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. EyePoint Plc's net income of -$59.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, EyePoint Plc's price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 29.59x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EYPTEyePoint Plc29.59x -- $966K -$59.7M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns EYPT or PTN?
Palatin Technologies has a net margin of -6183.44% compared to EyePoint Plc's net margin of --. EyePoint Plc's return on equity of -79.15% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EYPTEyePoint Plc25.36% -$0.85 $223.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About EYPT or PTN?
EyePoint Plc has a consensus price target of $36.08, signalling upside risk potential of 97.61%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than EyePoint Plc, analysts believe Palatin Technologies is more attractive than EyePoint Plc.
Company Buy Ratings Hold Ratings Sell Ratings EYPTEyePoint Plc10 0 0 PTNPalatin Technologies0 0 0 -
Is EYPT or PTN More Risky?
EyePoint Plc has a beta of 1.668, which suggesting that the stock is 66.808% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock EYPT or PTN?
EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EYPT or PTN?
EyePoint Plc quarterly revenues are $966K, which are larger than Palatin Technologies quarterly revenues of --. EyePoint Plc's net income of -$59.7M is higher than Palatin Technologies's net income of --. Notably, EyePoint Plc's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 29.59x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EYPTEyePoint Plc29.59x -- $966K -$59.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns EYPT or VKTX?
Viking Therapeutics, Inc. has a net margin of -6183.44% compared to EyePoint Plc's net margin of --. EyePoint Plc's return on equity of -79.15% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital EYPTEyePoint Plc25.36% -$0.85 $223.4M VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About EYPT or VKTX?
EyePoint Plc has a consensus price target of $36.08, signalling upside risk potential of 97.61%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 150.04%. Given that Viking Therapeutics, Inc. has higher upside potential than EyePoint Plc, analysts believe Viking Therapeutics, Inc. is more attractive than EyePoint Plc.
Company Buy Ratings Hold Ratings Sell Ratings EYPTEyePoint Plc10 0 0 VKTXViking Therapeutics, Inc.12 1 0 -
Is EYPT or VKTX More Risky?
EyePoint Plc has a beta of 1.668, which suggesting that the stock is 66.808% more volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.
-
Which is a Better Dividend Stock EYPT or VKTX?
EyePoint Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Plc pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EYPT or VKTX?
EyePoint Plc quarterly revenues are $966K, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. EyePoint Plc's net income of -$59.7M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, EyePoint Plc's price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Plc is 29.59x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EYPTEyePoint Plc29.59x -- $966K -$59.7M VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
